Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Unmet challenges in the use of novel agents in locally advanced non-small-cell lung cancer.
Decker RH, Lynch TJ.
J Clin Oncol. 2012 Feb 20;30(6):582-4. Epub 2012 Jan 23. No abstract available.
Related citations
Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study.
Hoang T, Dahlberg SE, Schiller JH, Mehta MP, Fitzgerald TJ, Belinsky SA, Johnson DH.
J Clin Oncol. 2012 Feb 20;30(6):616-22. Epub 2012 Jan 23.
Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.
Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH, Dive C.
J Clin Oncol. 2012 Feb 10;30(5):525-32. Epub 2012 Jan 17.
ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma.
Jänne PA, Meyerson M.
J Clin Oncol. 2012 Mar 10;30(8):878-9. Epub 2012 Jan 3. No abstract available.
Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.
Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, Ho BC, Chang GC, Shih JY, Yu SL, Yang PC.
J Clin Oncol. 2012 Feb 1;30(4):433-40. Epub 2012 Jan 3.
Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer.
Greer JA, Pirl WF, Jackson VA, Muzikansky A, Lennes IT, Heist RS, Gallagher ER, Temel JS.
J Clin Oncol. 2012 Feb 1;30(4):394-400. Epub 2011 Dec 27.
Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.
De Pas TM, Giovannini M, Manzotti M, Trifirò G, Toffalorio F, Catania C, Spaggiari L, Labianca R, Barberis M.
J Clin Oncol. 2011 Dec 1;29(34):e819-22. Epub 2011 Oct 31. No abstract available.
Induction chemotherapy and surgery for early-stage non-small-cell lung cancer: what have we learned from randomized trials?
Strauss GM.
J Clin Oncol. 2012 Jan 10;30(2):128-31. Epub 2011 Nov 28. No abstract available.
Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer.
Scagliotti GV, Pastorino U, Vansteenkiste JF, Spaggiari L, Facciolo F, Orlowski TM, Maiorino L, Hetzel M, Leschinger M, Visseren-Grul C, Torri V.
J Clin Oncol. 2012 Jan 10;30(2):172-8. Epub 2011 Nov 28.
Computed tomography-based simulation for thoracic radiation therapy: technical advance or clinical evidence?
Levy A, Magné N, Chargari C.
J Clin Oncol. 2011 Nov 10;29(32):4335-6; author reply 4336. Epub 2011 Oct 11. No abstract available.
Oxaliplatin-induced coronary vasospasm manifesting as Kounis syndrome: a case report.
Chang PH, Hung MJ, Yeh KY, Yang SY, Wang CH.
J Clin Oncol. 2011 Nov 1;29(31):e776-8. Epub 2011 Oct 3. No abstract available.
Perspectives of patients on the utility of electronic patient-reported outcomes on cancer care.
Seow H, King S, Green E, Pereira J, Sawka C.
J Clin Oncol. 2011 Nov 1;29(31):4213-4. Epub 2011 Sep 19. No abstract available.
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.
Ramalingam SS, Spigel DR, Chen D, Steins MB, Engelman JA, Schneider CP, Novello S, Eberhardt WE, Crino L, Habben K, Liu L, Jänne PA, Brownstein CM, Reck M.
J Clin Oncol. 2011 Dec 1;29(34):4574-80. Epub 2011 Oct 24.
Myxopapillary ependymoma with pleuropulmonary metastases and high plasma glial fibrillary acidic protein levels.
Ilhan A, Furtner J, Birner P, Rössler K, Marosi C, Preusser M.
J Clin Oncol. 2011 Oct 20;29(30):e756-7. Epub 2011 Sep 6. No abstract available.
Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.
Soria JC, Márk Z, Zatloukal P, Szima B, Albert I, Juhász E, Pujol JL, Kozielski J, Baker N, Smethurst D, Hei YJ, Ashkenazi A, Stern H, Amler L, Pan Y, Blackhall F.
J Clin Oncol. 2011 Nov 20;29(33):4442-51. Epub 2011 Oct 17.
Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.
Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM.
J Clin Oncol. 2011 Nov 10;29(32):4320-6. Epub 2011 Oct 11.
Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial.
Rusch VW, Hawes D, Decker PA, Martin SE, Abati A, Landreneau RJ, Patterson GA, Inculet RI, Jones DR, Malthaner RA, Cohen RG, Ballman K, Putnam JB Jr, Cote RJ.
J Clin Oncol. 2011 Nov 10;29(32):4313-9. Epub 2011 Oct 11.
Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost?
Shepherd FA.
J Clin Oncol. 2011 Nov 1;29(31):4068-70. Epub 2011 Oct 3. No abstract available.
Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy.
Parikh PM, Vaid A, Advani SH, Digumarti R, Madhavan J, Nag S, Bapna A, Sekhon JS, Patil S, Ismail PM, Wang Y, Varadhachary A, Zhu J, Malik R.
J Clin Oncol. 2011 Nov 1;29(31):4129-36. Epub 2011 Oct 3.
Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.
Ready NE, Dudek AZ, Pang HH, Hodgson LD, Graziano SL, Green MR, Vokes EE.
J Clin Oncol. 2011 Nov 20;29(33):4436-41. Epub 2011 Oct 3.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on